ORIC Pharmaceuticals (NASDAQ:ORIC - Free Report) had its price objective cut by Oppenheimer from $15.00 to $12.00 in a report published on Tuesday morning, Marketbeat reports. They currently have an outperform rating on the stock.
A number of other research analysts also recently commented on ORIC. Wedbush restated an "outperform" rating and set a $20.00 price objective on shares of ORIC Pharmaceuticals in a research note on Thursday, March 20th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of ORIC Pharmaceuticals in a report on Tuesday, May 6th. HC Wainwright reissued a "buy" rating and set a $21.00 target price on shares of ORIC Pharmaceuticals in a research note on Monday, May 5th. JPMorgan Chase & Co. upped their target price on shares of ORIC Pharmaceuticals from $21.00 to $22.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. Finally, Guggenheim reiterated a "buy" rating on shares of ORIC Pharmaceuticals in a research report on Wednesday, February 26th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $19.17.
Check Out Our Latest Report on ORIC Pharmaceuticals
ORIC Pharmaceuticals Stock Performance
Shares of ORIC stock traded down $0.24 during trading hours on Tuesday, hitting $5.08. 418,639 shares of the company were exchanged, compared to its average volume of 645,328. The stock has a market capitalization of $361.13 million, a price-to-earnings ratio of -2.79 and a beta of 1.37. ORIC Pharmaceuticals has a one year low of $3.90 and a one year high of $14.67. The business's 50-day simple moving average is $5.90 and its two-hundred day simple moving average is $8.06.
ORIC Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The company reported ($0.42) earnings per share for the quarter, beating analysts' consensus estimates of ($0.51) by $0.09. As a group, analysts anticipate that ORIC Pharmaceuticals will post -2.17 EPS for the current fiscal year.
Institutional Trading of ORIC Pharmaceuticals
Several institutional investors have recently modified their holdings of the company. KLP Kapitalforvaltning AS bought a new stake in ORIC Pharmaceuticals in the fourth quarter worth about $50,000. Arizona State Retirement System acquired a new stake in ORIC Pharmaceuticals during the first quarter valued at approximately $56,000. BNP Paribas Financial Markets acquired a new position in ORIC Pharmaceuticals in the fourth quarter worth approximately $71,000. PNC Financial Services Group Inc. lifted its position in shares of ORIC Pharmaceuticals by 22.9% during the 4th quarter. PNC Financial Services Group Inc. now owns 13,517 shares of the company's stock valued at $109,000 after acquiring an additional 2,520 shares during the last quarter. Finally, Legato Capital Management LLC bought a new stake in shares of ORIC Pharmaceuticals during the 1st quarter worth $109,000. Institutional investors and hedge funds own 95.05% of the company's stock.
About ORIC Pharmaceuticals
(
Get Free Report)
ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.
Featured Articles

Before you consider ORIC Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ORIC Pharmaceuticals wasn't on the list.
While ORIC Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.